Mr Emmanuel Ndashimye, BBLT - University of Western Ontario - PhD candidate

Mr Emmanuel Ndashimye


University of Western Ontario

PhD candidate

London, Ontario | Canada

Main Specialties: Biology, Clinical & Laboratory Immunology, Epidemiology, Infectious Disease, Medical Microbiology

ORCID logo

Top Author

Mr Emmanuel Ndashimye, BBLT - University of Western Ontario - PhD candidate

Mr Emmanuel Ndashimye



• Emmanuel Ndashimye completed his Biomedical Laboratory science degree from Makerere University, Kampala, Uganda in 2010.
• He then worked as a laboratory technologist at National Tuberculosis Reference Laboratory, Kampala, Uganda for 1 year.
• He moved on to work as Head drug resistance services/research assistant at Center For AIDS Research (CFAR) Laboratories at Joint Clinical Research Center, Kampala, Uganda for 5 years. He conducted and monitored patient and research studies for HIV-1 drug resistance testing and trained undergraduate students.
• Pursued Global Health Systems course at University of Western Ontario, Canada
• He is pursuing PhD degree in microbiology and immunology at University of Western Ontario, Canada under supervision of Dr. Eric J Arts. His current research focuses on HIV drug resistance, treatment, integration, and vaccine.
• At Western university, he works as a teaching assistant in microbiology and Immunology department, and language/cultural instructor for Global Health Systems program.
• He is author/coauthor of 19 peer-review publications in HIV research
• He has given several talks and poster presentations in numerous local and international scientific conferences
• He has received numerous awards, including, Queen Elizabeth II Diamond Jubilee scholarship (collaborative research and training), Ontario Graduate Scholarship, Young researcher and best poster award, Advanced Virologic Laboratory Training scholarship, and travel awards.
• He is a reviewer of highly prestigious peer-reviewed scientific journals

Primary Affiliation: University of Western Ontario - London, Ontario , Canada


Research Interests:

View Mr Emmanuel Ndashimye’s Resume / CV


Sep 2016
Western University
Global Health Systems in Africa
Aug 2015
Case Western Reserve University
Advanced Virologic Laboratory Training
Aug 2006 - Jan 2010
Makerere University
Biomedical Laboratory Technology


Aug 2014
WHO accreditation-Center for AIDS Research laboratory
Laboratory preparations
Apr 2011 - Apr 2011
Joint Clinical Research Center-Center For AIDS Research
Research Assistant/Head drug resistance services
Apr 2011
DART, ARROW, EARNEST clinical trials
Coordinator-HIV drug resistance




31Profile Views

26PubMed Central Citations

The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030.

Infect Dis Poverty 2019 Aug 2;8(1):63. Epub 2019 Aug 2.

Department of Microbiology and Immunology, Western University, 1151 Richmond St., DSB Rm.3007, London, ON, N6A5C1, Canada.

View Article

Download full-text PDF

Source Listing
August 2019
3 Reads

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index.

Health and quality of life outcomes

BACKGROUND:Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM). METHODS:This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions. RESULTS:In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar. CONCLUSIONS:Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution. TRIAL REGISTRATION:NCT00988039 . Registered 30 September 2009.

View Article
May 2019
8 Reads

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

AIDS Res Hum Retroviruses 2018 05 26;34(5):404-414. Epub 2018 Feb 26.

1 Department of Microbiology and Immunology, Western University , London, Canada .

View Article

Download full-text PDF

Source Listing
May 2018
30 Reads
2.330 Impact Factor

High Time to Start Human Immunodeficiency Virus Type 1-Infected Patients on Integrase Inhibitors in Sub-Saharan Africa.

J Infect Dis 2017 07;216(2):283-284

Department of Microbiology and Immunology, Western University, London, Ontario,Canada.

View Article

Download full-text PDF

Publisher Site Listing
July 2017
6 Reads
5.997 Impact Factor

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

J Acquir Immune Defic Syndr 2017 06;75(2):e45-e54

*Joint Clinical Research Centre (JCRC), Kampala, Uganda; †MRC Clinical Trials Unit at University College London, London, United Kingdom; ‡University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe; §Infectious Diseases Institute, Kampala, Uganda; ‖Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; ¶Dignitas International, Zomba, Malawi; #Department of Medicine, Moi University School of Medicine, Eldoret, Kenya; **World Health Organisation, Geneva, Switzerland; and ‡‡Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

View Article

Download full-text PDF

Source Listing
June 2017
40 Reads
4.556 Impact Factor

Once vs twice-daily abacavir and lamivudine in African children.

AIDS 2016 07;30(11):1761-70

aJoint Clinical Research Centre bDepartment of Paediatrics and Child Health, College of Health Sciences, Makerere University cBaylor-Uganda, Paediatric Infectious Diseases Clinic, Mulago Hospital, Kampala, Uganda dMedical Research Council (MRC) Clinical Trials Unit at University College London, London, UK eMedical Research Council/Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda fUniversity of Zimbabwe, Harare, Zimbabwe gViiV HealthCare, Brentford, Middlesex, UK. *Diana M. Gibb and Ann Sarah Walker contributed equally to the writing of this manuscript.

View Article

Download full-text PDF

Source Listing
July 2016
79 Reads
4 Citations
5.554 Impact Factor

Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Antimicrob Agents Chemother 2016 06 23;60(6):3380-97. Epub 2016 May 23.

Center for AIDS Research Uganda Laboratories, Joint Clinical Research Centre, Kampala, Uganda Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA University Hospital Translational Laboratory, University Hospitals Case Medical Center, Cleveland, Ohio, USA

View Article

Download full-text PDF

Source Listing
June 2016
38 Reads
10 Citations
4.480 Impact Factor